Newshot

Isomorphic Labs raises $5 billion in its second mega-round within six months

Summary

Isomorphic Labs has raised $5 billion, just six months after a $2.1 billion round. Alphabet's AI drug discovery company, led by Demis Hassabis, plans to use the funding to push its drug pipeline toward clinical trials. The company has no approved drugs yet. The article Isomorphic Labs raises $5 billion in its second mega-round within six months appeared first on The Decoder .

Original text(via The Decoder)

Isomorphic Labs raises $5 billion in its second mega-round within six months

题图
题图

Alphabet's AI drug discovery company Isomorphic Labs has raised $5 billion, its second billion-dollar round in six months. Greenoaks and Sequoia Capital co-led the round, joined by new backer Andreessen Horowitz along with Alphabet and all existing investors.

The company had already raised $2.1 billion back in May 2026. The money will go toward advancing its in-house platform IsoDDE (Isomorphic Drug Design Engine) and pushing its drug pipeline toward clinical trials. IsoDDE goes beyond AlphaFold 3, according to the company founded in 2021, and aims to better predict drug binding and docking sites. Isomorphic Labs works with Novartis, Eli Lilly, and Johnson & Johnson but has no approved drug to show for it yet.

The company is led by Demis Hassabis, who stepped down from day-to-day leadership of Google Deepmind in August 2026 and now serves as Alphabet's Chief Scientist. Hassabis won the 2024 Nobel Prize in Chemistry alongside John Jumper for their work on AlphaFold.

Deepmind's original AlphaFold team was disbanded in July 2026. Many researchers moved to Isomorphic Labs or were reassigned to other projects. Nearly a quarter left Deepmind entirely. Deepmind still shipped AlphaGenome 2 in early November 2026, which predicts how DNA variants affect gene activity in specific cell types.

AI News Without the Hype – Curated by Humans

Subscribe to THE DECODER for ad-free reading, a weekly AI newsletter, our exclusive "AI Radar" frontier report six times a year, full archive access, and access to our comment section.

The text above was extracted automatically from the source page and may miss images, tables or code blocks. The original is authoritative.

Published by The Decoder
This site only summarises and aggregates; copyright stays with the original author. Headlines and summaries follow the source — where they differ, the original wins.
Read the original ↗